HCV clinical trial application submitted to Recombinant DNA Advisory Committee (RAC)
– Benitec progresses hepatitis C therapeutic towards the clinic
SYDNEY, April 16, 2013 /PRNewswire/ — RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced that the company’s wholly owned US subsidiary, Tacere Therapeutics Inc., has submitted an application to the US National Institutes of Health’s Recombinant DNA Advisory Committee (RAC) .
The RAC submission document comprises the full clinical trial protocol for its first-in-man ddRNAi-based therapeutic (TT-034) for hepatitis C virus (HCV) infection, as well as the safety and toxicology data and responses to questions concerning the objective and rationale for the proposed trial. Most of this material will be utilised in the subsequent US Food and Drug Administration (FDA) Investigational New Drug (IND) application for TT-034.
The RAC review is a required step for a product that involves gene therapy vectors before a clinical trial can be initiated. The RAC process results in recommendations that are disseminated to various bodies, including the Company and the FDA. The review can be administrative or include a public hearing. If the application is subject to a hearing, this is expected to be part of the next RAC meeting in June 2013.
David Suhy, Ph.D., Tacere’s US-based, Senior Vice President of Research and Development commented, “Completing this submission is an important step in moving TT-034 into the clinic. We look forward to receiving the Committee’s recommendations and then moving ahead with an IND and initiating the clinical trial for TT-034 this year. It has been very gratifying to oversee the development of a first-in-class therapeutic from concept to the clinic.”
TT-034 is a potentially transformative therapeutic that is intended to provide a “one-shot-cure” for hepatitis C with a single injection. Preclinical studies have shown that the vector used to deliver TT-034 specifically targets liver cells where it transfects almost every cell without causing toxic effects. TT-034 is designed to prevent development of viral resistance (a major problem for most hepatitis C drugs) by simultaneously silencing three separate highly conserved regions on the virus genome. Studies have demonstrated that a single treatment of TT-034 is active out to 180 days (the duration of the studies).
About Benitec Biopharma Limited:
Benitec Biopharma Limited (ASX Code: BLT), based in Sydney, Australia, has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for a range of chronic and life-threatening human conditions. Benitec has licensed its ddRNAi technology to other biopharmaceutical companies who are advancing their programs toward the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington’s disease. For more information on Benitec refer to the Company’s website at www.benitec.com.
For more information please contact:
Dr Peter French | Chief Executive Officer
Phone: +61 (02) 9555 6986 | firstname.lastname@example.org | www.benitec.com
SOURCE Benitec Biopharma Limited